EUVIMEDEUVIMED entdecken
Multizentrische Studie

Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU

María José Casanova, Berta Caballol, María José García, Francisco Mesonero, Cristina Rubín de Célix, Patricia Suárez-Álvarez, Rocío Ferreiro-Iglesias, María Del Mar Martín-Rodríguez, Ruth de Francisco, Pilar Varela-Trastoy, Guillermo Bastida, Marta Carrillo-Palau und 35 weitere

Digestive and Liver Disease · 2024

DOI: 10.1016/j.dld.2024.05.009 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von María José Casanova und 46 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autó…. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized, Ustekinumab, Rectal Fistula. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Takeda Pharmaceutical Company, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The efficacy of ustekinumab and vedolizumab for treating complex perianal fistula in Crohn's disease has been barely studied. We aimed to assess treatment persistence, clinical remission, and safety of these drugs in this context. METHODS: Crohn's disease patients who had received ustekinumab or vedolizumab for the indication of active complex perianal fistula, were included. Clinical remission was defined according to Fistula Drainage Assessment Index (no drainage through the fistula upon gentle pressure) based on physicians' assessment. RESULTS: Of 155 patients, 136 received ustekinumab, and 35 vedolizumab (16 received both). Median follow-up for ustekinumab was 27 months. Among those on ustekinumab, 54 % achieved remission, and within this group, 27 % relapsed during follow-up. The incidence rate of relapse was 11 % per patient-year. Multivariate analysis found no variables associated with treatment discontinuation or relapse. Median follow-up time for patients receiving vedolizumab was 19 months. Remission was achieved in 46 % of the patients receiving vedolizumab, and among them, 20 % relapsed during follow-up. The incidence rate of relapse was 7 % per patient-year. Adverse events were mild in 6 % on ustekinumab and 8 % on vedolizumab. CONCLUSION: Ustekinumab and vedolizumab appear effective, achieving remission in around half of complex perianal fistula patients, with favorable safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, Monoclonal, HumanizedUstekinumabRectal FistulaGastrointestinal AgentsRemission InductionHumansFemaleMaleAdultMiddle AgedRecurrenceTreatment OutcomeMultivariate Analysis

Stichwörter der Autor:innen

Complex perianal fistulaUstekinumabVedolizumab

Substanzen

Antibodies, Monoclonal, HumanizedUstekinumabvedolizumabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de…
  • Department of Gastroenterology, Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and CIBEREHD, Barcelona, Spain.
  • Department of Gastroenterology, Hospital Universitario Marqués de Valdecilla and Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain.
  • Department of Gastroenterology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Department of Gastroenterology, Complejo Asistencial Universitario de León, León, Spain.
  • Department of Gastroenterology, Hospital Clínico Universitario de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Förderung

  • Takeda Pharmaceutical Company
  • Pfizer

Zitieren

APA

Casanova, M. J., Caballol, B., García, M. J., Mesonero, F., Rubín de Célix, C., Suárez-Álvarez, P., Ferreiro-Iglesias, R., Martín-Rodríguez, M. D. M., de Francisco, R., Varela-Trastoy, P., Bastida, G., Carrillo-Palau, M., Núñez-Ortiz, A., Ramírez-de la Piscina, P., Ceballos, D., Hervías-Cruz, D., Muñoz-Pérez, R., Velayos, B., Bermejo, F., …, & HEAL Study group of GETECCU (2024). Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2024.05.009

Vancouver

Casanova MJ, Caballol B, García MJ, Mesonero F, Rubín de Célix C, Suárez-Álvarez P, et al. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2024.05.009

BibTeX
@article{Casanova2024,
  author = {Casanova, María José and Caballol, Berta and García, María José and Mesonero, Francisco and Rubín de Célix, Cristina and Suárez-Álvarez, Patricia and Ferreiro-Iglesias, Rocío and Martín-Rodríguez, María Del Mar and de Francisco, Ruth and Varela-Trastoy, Pilar and Bastida, Guillermo and Carrillo-Palau, Marta and Núñez-Ortiz, Andrea and Ramírez-de la Piscina, Patricia and Ceballos, Daniel and Hervías-Cruz, Daniel and Muñoz-Pérez, Roser and Velayos, Benito and Bermejo, Fernando and Busquets, David and Cabacino, Manuel and Camo-Monterde, Patricia and Marín-Jiménez, Ignacio and Muñoz, Carmen and de la Peña-Negro, Luisa Carmen and Sierra-Moros, Eva and Barrio, Jesús and Brunet-Mas, Eduard and Bujanda, Luis and Cañete, Fiorella and Gomollón, Fernando and Manceñido-Marcos, Noemí and Rodríguez-Lago, Iago and Rodríguez-Grau, María Carmen and Sicilia, Beatriz and Torra-Alsina, Sandra and Arranz-Hernández, Laura and Carpio, Daniel and García-Sepulcre, Mariana Fe and González-Muñoza, Carlos and Huguet, José María and Márquez-Mosquera, Lucía and López-Serrano, María Pilar and Ponferrada-Díaz, Ángel and Chaparro, María and Gisbert, Javier P and HEAL Study group of GETECCU, HEAL Study group of GETECCU},
  title = {Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU},
  journal = {Digestive and Liver Disease},
  year = {2024},
  doi = {10.1016/j.dld.2024.05.009}
}
Kostenlos starten →